Literature DB >> 18022271

Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.

Lars H Lindner1, Martin Hossann, Michael Vogeser, Nicole Teichert, Kirsten Wachholz, Hansjoerg Eibl, Wolfgang Hiddemann, Rolf D Issels.   

Abstract

Lysolipid-based thermosensitive liposomes have been successfully introduced as efficient drug delivery system with fast drug release upon heat treatment. Hexadecylphosphocholine (HePC) is structurally related to 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine (P-lyso-PC) but chemically and metabolically more stable, thereby offering strong antineoplastic, antiprotozoal and antifungal activity. We investigated the properties of HePC in low temperature sensitive (LTSL) and high temperature sensitive liposomes (HTSL) based on 1,2-dipalmitoyl-sn-glycero-3-phosphoglyceroglycerol (DPPGOG). Therefore liposomes composed of DPPC/DSPC=8:2 (molar ratio), DPPC/DSPC/DPPGOG=5:2:3, HePC/DPPC/DSPC/DPPGOG=1:4:2:3, HePC/DSPC/DPPGOG=1:6:3 and P-lyso-PC/DPPC/DSPC/DPPGOG=1:4:2:3 were prepared by the lipid film hydration and extrusion method and compared with regard to stability at 37 degrees C and the release kinetics under heating conditions (38 degrees C-45 degrees C) in the presence of fetal calf serum. Each formulation was characterized for size distribution, zeta-potential, encapsulation efficiency and phase transition temperature (T(m)). The influence of heat on the cytotoxic activity of HePC in TSL was investigated using the WST-1 assay in BFS-1 fibrosarcoma and C6 glioma cells for the low (HePC-LTSL, T(m)=42.9 degrees C) and the high (HePC-HTSL, T(m)=48.5 degrees C) temperature sensitive formulations and compared to micellar HePC or plain TSL. The cellular HePC uptake after 15 min incubation at 37 degrees C or 42 degrees C was determined by liquid chromatography tandem-mass spectrometry (LC-MS/MS). As expected, HePC increases the release rate of TSL similar to lysolipid. The cytotoxicity of HePC in TSL was heat inducible and stronger than the one induced by micellar HePC which did not respond to heat. A possible explanation for this raise in cytotoxicity of HePC in TSL is the increased cellular transfer of HePC under heating conditions demonstrated by LC-MS/MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022271     DOI: 10.1016/j.jconrel.2007.10.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  17 in total

1.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

Review 2.  Transport of drugs from blood vessels to tumour tissue.

Authors:  Mark W Dewhirst; Timothy W Secomb
Journal:  Nat Rev Cancer       Date:  2017-11-10       Impact factor: 60.716

3.  In vitro Measurement of Release Kinetics of Temperature Sensitive Liposomes with a Fluorescence Imaging System.

Authors:  Davud Asemani; Anjan Motamarry; Dieter Haemmerich
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2018-07

4.  Drug release kinetics of temperature sensitive liposomes measured at high-temporal resolution with a millifluidic device.

Authors:  Caitlin Burke; Matthew R Dreher; Ayele H Negussie; Andrew S Mikhail; Pavel Yarmolenko; Aakash Patel; Brenden Skilskyj; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2017-12-28       Impact factor: 3.914

5.  Temperature-sensitive liposome-mediated delivery of thrombolytic agents.

Authors:  Vishal Saxena; Carmen Gacchina Johnson; Ayele H Negussie; Karun V Sharma; Matthew R Dreher; Bradford J Wood
Journal:  Int J Hyperthermia       Date:  2015-03-13       Impact factor: 3.914

6.  Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.

Authors:  Simone Limmer; Jasmin Hahn; Rebecca Schmidt; Kirsten Wachholz; Anja Zengerle; Katharina Lechner; Hansjörg Eibl; Rolf D Issels; Martin Hossann; Lars H Lindner
Journal:  Pharm Res       Date:  2014-03-06       Impact factor: 4.200

7.  Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.

Authors:  Ashley A Manzoor; Lars H Lindner; Chelsea D Landon; Ji-Young Park; Andrew J Simnick; Matthew R Dreher; Shiva Das; Gabi Hanna; Won Park; Ashutosh Chilkoti; Gerben A Koning; Timo L M ten Hagen; David Needham; Mark W Dewhirst
Journal:  Cancer Res       Date:  2012-09-04       Impact factor: 12.701

Review 8.  The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

Authors:  Michael L Etheridge; Stephen A Campbell; Arthur G Erdman; Christy L Haynes; Susan M Wolf; Jeffrey McCullough
Journal:  Nanomedicine       Date:  2012-06-06       Impact factor: 5.307

9.  Effects of Surface Charge, PEGylation and Functionalization with Dipalmitoylphosphatidyldiglycerol on Liposome-Cell Interactions and Local Drug Delivery to Solid Tumors via Thermosensitive Liposomes.

Authors:  Matteo Petrini; Wouter J M Lokerse; Agnieszka Mach; Martin Hossann; Olivia M Merkel; Lars H Lindner
Journal:  Int J Nanomedicine       Date:  2021-06-14

10.  Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Frank Rattay; Bradford J Wood; Dieter Haemmerich
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.